ENMD-2076 tartrate
| Code | Size | Price |
|---|
| TAR-T2358L-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T2358L-50mg | 50mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
ENMD-2076 is an orally active kinase inhibitor. It also has antiangiogenic and antiproliferative mechanisms of action.
CAS:
1453868-32-0
Formula:
C25H31N7O6
Molecular Weight:
525.566
Purity:
0.98
SMILES:
O[C@H]([C@@H](O)C(O)=O)C(O)=O.CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(C=Cc2ccccc2)n1
References
1. Chiba Y, Sato S, Itamochi H, Yoshino N, Fukagawa D, Kawamura H, Suga Y, Kojima-Chiba A, Muraki Y, Sugai T, Sugiyama T. Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma Cell Lines Induced by Cisplatin: A Potential Treatment Strategy. Int J Gynecol Cancer. 2017 Oct;27(8):1666-1674. doi: 10.1097/IGC.0000000000001081. PubMed PMID: 28786875.
2. Ionkina AA, Tentler JJ, Kim J, Capasso A, Pitts TM, Ryall KA, Howison RR, Kabos P, Sartorius CA, Tan AC, Eckhardt SG, Diamond JR. Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer. Front Oncol. 2017 May 15;7:94. doi: 10.3389/fonc.2017.00094. eCollection 2017. PubMed PMID: 28555173; PubMed Central PMCID: PMC5430301.
3. Yee KW, Chen HW, Hedley DW, Chow S, Brandwein J, Schuh AC, Schimmer AD, Gupta V, Sanfelice D, Johnson T, Le LW, Arnott J, Bray MR, Sidor C, Minden MD. A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia. Invest New Drugs. 2016 Oct;34(5):614-24. doi: 10.1007/s10637-016-0375-2. Epub 2016 Jul 12. PubMed PMID: 27406088.
4. Falchook GS, Bastida CC, Kurzrock R. Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress. Semin Oncol. 2015 Dec;42(6):832-48. doi: 10.1053/j.seminoncol.2015.09.022. Epub 2015 Sep 24. Review. PubMed PMID: 26615129.